GlassScriptPhysician profile
Stacey M Perry
NPI 1205384880
$4,532.52
in general payments reported to CMS, 2019-2025
40 companies · $56.47 in 2025
The $56.47 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $592 · 2022: $1,589 · 2023: $1,939 · 2024: $357 · 2025: $56.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.03 |
| Education | $269.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $432.97 | 2021-2023 | Erleada, Darzalex, Imbruvica |
| Daiichi Sankyo INC. | $432.28 | 2021-2023 | Enhertu, Injectafer |
| Seagen INC. | $385.88 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Pfizer INC. | $360.39 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $342.97 | 2021-2025 | Kisqali, Piqray |
| Pharmacyclics LLC, An Abbvie Company | $322.06 | 2021-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $248.91 | 2021-2023 | Pomalyst, Reblozyl |
| Amgen INC. | $189.82 | 2021-2023 | Lumakras, Vectibix, Xgeva |
| Merck Sharp & Dohme LLC | $133.33 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Jazz Pharmaceuticals INC. | $127.53 | 2021-2024 | |
| Genentech USA, INC. | $119.71 | 2022-2023 | Lunsumio, Polivy, Columvi |
| Glaxosmithkline, LLC. | $119.13 | 2021-2024 | Shingrix, Zejula, Jemperli |
| Eisai INC. | $101.64 | 2022-2023 | |
| Beigene USA, INC. | $99.34 | 2022-2024 | Brukinsa |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.